Yamei Xu

ORCID: 0000-0001-9969-613X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Viral Infections and Immunology Research
  • IL-33, ST2, and ILC Pathways
  • Cardiovascular Effects of Exercise
  • Heart Failure Treatment and Management
  • Cardiovascular Function and Risk Factors
  • Acute Myocardial Infarction Research
  • Cardiomyopathy and Myosin Studies
  • Oral Health Pathology and Treatment
  • Phytochemical and Pharmacological Studies
  • Inflammasome and immune disorders

Fudan University
2020-2025

Zhongshan Hospital
2020-2025

Shanghai Institute of Hematology
2020

The First Affiliated Hospital, Sun Yat-sen University
2020

Sun Yat-sen University
2020

Background and purpose: With the implementation of Chest Pain Centers program, significant advancements have been achieved in managing risk factors providing coronary interventional treatments China. However, a notable gap exists understanding occurrence de novo heart failure (HF) following ST-segment elevation myocardial infarction (STEMI). This study aimed to describe incidence, clinical characteristics, related factors, prognostic significance HF after STEMI contemporary Methods: cohort...

10.1097/cp9.0000000000000108 article EN cc-by-nc-nd Cardiology Plus 2025-01-28

BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for lacking. Whereas mRNA-based therapies have shown efficacy humans, their therapeutic potential cardiomyopathies remains unclear. METHODS: Whole-exome sequencing identified a novel DSC2 sequence variation causing autosomal recessive...

10.1161/circulationaha.124.072340 article EN Circulation 2025-04-11
Coming Soon ...